Biote Corp. (BTMD)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$1.21+8.04%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
QuarterlyIQ Insights · BTMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -78.6% |
| Our one-year growth estimate | diamond | 1.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 80.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers · Company calendar date is not available
BTMD — CEO transition
Dated 2026-06-17
Interim Chief Executive Officer — Mr. Peterson: Mr. Peterson was appointed as Interim Chief Executive Officer with a new employment agreement.
Why it matters: Supplement sales grew in both Q1 and Q2, even as procedure sales fell. Continued growth would support the full-year goal.
Supportive ifQ3 dietary supplement revenue is above $11.4 million and up year over year.
Worry ifQ3 dietary supplement revenue is $11.4 million or lower, or falls year over year.
Why it matters: Bob Peterson became interim CEO in June. A named successor would clarify who leads the company’s next steps.
Watch forBiote names a permanent CEO and sets out how that leader will carry out its stated business plans.
Also watch forBiote says Peterson is still interim CEO, or names a successor but gives no clear leadership plan.
Why it matters: The recall raised product costs and cut plant output. A margin gain would show those pressures easing.
Supportive ifQ3 gross margin is above 65.4%, the Q2 level.
Worry ifQ3 gross margin is 65.4% or lower, showing no margin recovery.
Why it matters: Procedure revenue fell 13.9% in Q2 after the recall. A rise would show the recovery is starting.
Supportive ifQ3 procedure revenue tops $30.3 million, the Q2 level. This shows growth from Q2.
Worry ifQ3 procedure revenue is $30.3 million or less. It shows no growth from Q2.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $856 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,485 loss on $10,000 · 64.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.